| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Company to host conference call and webcast today at 8:00 a.m. ET |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
Company to host conference call and webcast today at 8:00 a.m. EDT |
| 25 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
1.Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’s business. |
| 21 May 2026 |
8-K: Regulation FD Disclosure
1 PROTALIX BIOTHERAPEUTICS C O R P O R A T E P R E S E N T A T I O N J u n e 2024 PROTALIX BIOTHERAPEUTICS Pioneering solutions to transform the treatment of rare diseases C O R P O R A T E P R E S E N T A T I O N M a y 2026 |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
Company to host conference call and webcast today at 8:00 a.m. EDT |
| 18 Mar 2026 |
8-K: Results of Operations and Financial Condition
Company to host conference call and webcast today at 8:00 a.m. EDT |
| 09 Mar 2026 |
8-K: Other Events
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) |
| 11 Feb 2026 |
8-K: Regulation FD Disclosure
1 PROTALIX BIOTHERAPEUTICS C O R P O R A T E P R E S E N T A T I O N J u n e 2024 PROTALIX BIOTHERAPEUTICS Pioneering solutions to transform the treatment of rare diseases C O R P O R A T E P R E S E N T A T I O N F e b r u a r y 2026 Ex... |
| 30 Jan 2026 |
8-K: Other Events
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU |
| 05 Jan 2026 |
8-K: Regulation FD Disclosure
CARMIEL, Israel, January 5, 2026 — Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with... |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
Company to host conference call and webcast today at 8:00 a.m. EST |
| 03 Nov 2025 |
8-K: Other Events
Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU |
| 17 Oct 2025 |
8-K: Regulation FD Disclosure; Other Events
1 PROTALIX BIOTHERAPEUTICS C O R P O R A T E P R E S E N T A T I O N J u n e 2024 PROTALIX BIOTHERAPEUTICS Pioneering solutions to transform the treatment of rare diseases C O R P O R A T E P R E S E N T A T I O N O c t o b e r 2025 Exhi... |
| 22 Aug 2025 |
8-K: Entry into a Material Definitive Agreement
Reference is made to the At The Market Offering Agreement, dated as of February 27, 2023, as amended on March 17, 2025 (the “ATM Agreement”), between Protalix BioTherapeutics, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwri... |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition
Company to host conference call and webcast today at 8:30 a.m. EDT |
| 01 Aug 2025 |
8-K: Other Events
On August 1, 2025, Protalix BioTherapeutics, Inc. (the “Company”) announced the dismissal of a claim against the Company and its Board of Directors (the “Board”). On March 10, 2025, plaintiff Kevin Mathew Thomas (“Plaintiff”) filed a Ver... |
| 21 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation
This EMPLOYMENT AGREEMENT (this “Agreement”) is made effective as of June 13, 2025 (the “Effective Date”), by and between Protalix Ltd., a company organized under the laws of the State of Israel (the “Company”) and Mr. Gilad Mamlok (the ... |
| 26 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Protalix Biotherapeutics, Inc. (the “Company”) convened its 2025 Annual Meeting of Stockholders (the “Meeting”) at 8:00 A.M. EDT on June 26, 2025 at the offices of Gornitzky & Co., The Vitania Tel Aviv Tower, 20 HaHarash Street, Tel Aviv... |
| 09 May 2025 |
8-K: Results of Operations and Financial Condition
Company to host conference call and webcast today at 8:30 a.m. EDT |
| 23 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On April 21, 2025, Eyal Rubin, Sr. Vice President and Chief Financial Officer of Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”), provided the Company and the Company’s Board of Directors with six months’ notice of... |
Loading...